- Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 2012.
- Johnston, L.D.; O’Malley, P.M.; Bachman, J.G.; and Schulenberg, J.E. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2013. Ann Arbor: Institute for Social Research, the University of Michigan, 2014.
- Hibell, B.; Guttormsson, U.; Ahlström, S.; Balakireva, O.; Bjarnason, T.; Kokkevi, A.; and Kraus, L. The 2011 ESPAD Report: Substance Use Among Students in 36 European Countries. Stockholm, Sweden: The Swedish Council for Information on Alcohol and Other Drugs (CAN), 2012.
- Bogenschutz, M.P.; and Pommy, J.M. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal 4(7–8): 543–555, 2012.
- Bonson, K.R. Hallucinogenic Drugs. In Encyclopedia of Life Sciences, Nature Publishing Group, 2001.
- Passie, T.; Halpern, J.H.; Stichtenoth, D.O.; Emrich, H.M.; and Hintzen, A. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci Ther 14(4): 295–314, 2008.
- Nichols, D.E. Hallucinogens. Pharmacol Ther 101(2): 131–181, 2004.
- Schindler, E.A.; Dave, K.D.; Smolock, E.M.; Aloyo, V.J.; and Harvey, J.A. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (+/-)-1-(2,5-dimethoxy- 4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacol Biochem Behav 101(1): 69–76, 2012.
- Lee, H.M.; and Roth, B.L. Hallucinogen actions on human brain revealed. Proc Natl Acad Sci U S A 109(6): 1820–1821, 2012.
- Morgan, C.J.; Curran, H.V.; and Independent Scientific Committee on Drugs. Ketamine use: A review. Addiction 107(1): 27–38, 2012.
- Morris, B.J.; Cochran, S.M.; and Pratt, J.A. PCP: From pharmacology to modelling schizophrenia. Curr Opin Pharmaco 5(1):101–106, 2005.
- Cunningham, C.W.; Rothman, R.B.; and Prisinzano, T.E. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63(2): 316–347, 2011.
- MacLean, K.A.; Johnson, M.W; Reissig, C.J.; Prisinzano, T.E.; and Griffiths, R.R. Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl). 226(2): 381–392, 2013.
This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.
As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.